BioCentury
ARTICLE | Finance

Precirix building out radiotherapy platform with €80M series B

The Belgian company is branching out into alpha emitters and growing its geographical footprint

March 18, 2022 8:16 PM UTC

With clinical studies of its lead iodine-based candidate under way, Precirix is deploying its series B to  expand its pipeline into other radioisotopes, including alpha-emitters.

“We want to demonstrate that we have a platform on our hands, not just one product,” CEO Ruth Devenyns told BioCentury...